Old drug, new trick: Repurposing metformin for gynecologic cancers?

Gynecologic Oncology

Volumn 135, Issue 3, 2014, Pages 614-621

  Febbraro, Terri ^a   Lengyel, Ernst ^a   Romero, Iris L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Endometrial cancer; Glucose; Gynecologic cancer; Metformin; Ovarian cancer

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; ORGANIC CATION TRANSPORTER 1; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; ENDOMETRIUM CANCER; ENZYME ACTIVATION; FATTY ACID OXIDATION; GLYCOLYSIS; GYNECOLOGIC CANCER; HUMAN; INSULIN SENSITIVITY; OVARY CANCER; OVARY TUMOR; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX TUMOR; UTERUS CANCER; FEMALE; GENITAL NEOPLASMS, FEMALE;

FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; METFORMIN;

EID: 84920761845     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.10.011     Document Type: Review

References (85)

1. Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007;448:645-6.
2. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. Br Med J 2005;530:1304-5.
3. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-8.
4. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JMM. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-5.
5. Landman GW, Kleefstra N, van Hateren KJJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010;33:322-6.
6. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013;8:e71583.
7. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res 2010;3:1451-61.
8. Hanahan D,Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144: 646-74.
9. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7:763-77.
10. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt M, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011;17:1498-503.
11. Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipocyte tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 1831;2013:1533-41.
12. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
13. Dowling R, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: Translational challenges. J Mol Endocrinol 2012;48:31-43.
14. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74.
15. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348(Pt 3):607-14.
16. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642-6.
17. Algire C, Moiseeva O, Deschenes-Simard X, Amrein L, Petruccelli L, Birman E, et al. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res (Phila) 2012;5:536-43.
18. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014;510:542-6.
19. Blandino G, ValerioM, CioceM,Mori F, Casadei L, Pulito C, et al. Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun 2012;3. http://dx.doi.org/10.1038/ncomms859.
20. Oliveras-Ferraros C, Cufi S, Vazquez-Martin A, Torres-Garcia VZ, Del Barco S,Martin- Castillo B, et al. Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFbeta-induced oncomiR miRNA-181a. Cell Cycle 2011;10:1144-51.
21. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together wtih chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69:7507-11.
22. Bao B,Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) 2012;5:355-64.
23. Shank JJ, Yang K, Ghannam J, Cabrera L, Johnston CJ, Reynolds RK, et al. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol 2012;127:390-7.
24. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
25. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev 2011;11: 719-25.
26. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008;110: 246-50.
27. Rattan R, Giri S, Hartmann LC, Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 2011;15:166-78.
28. Chan DK, Miskimins WK. Metformin and phenethyl isothiocyanate combined treatment in vitro is cytotoxic to ovarian cancer cultures. J Ovarian Res 2012;5:19.
29. Wu B, Li S, Sheng L, Zhu J, Gu L, Shen H, et al. Metformin inhibits the development and metastasis of ovarian cancer. Oncol Rep 2012;28:903-8.
30. Lengyel E, Litchfield L,Mitra AK, Nieman KM, Mukherjee A, Zhang Y, et al. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol 2014. http://dx.doi.org/10.1016/j.ajog.2014.10.026.
31. Liao H, Zhou Q, Gu Y, Duan T, Feng Y. Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway. Oncol Rep 2012;27:1873-8.
32. Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak MN, Gotlieb WH. Induction of apoptosis bymetformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins. Gynecol Oncol 2011;121:492-8.
33. Li C, Liu VW, Chan DW, Yao KM, Ngan HY. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells. Int J Gynecol Cancer 2012;22:15-22.
34. Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 2011;13:483-91.
35. Tebbe C, Chhina J, Dar SA, Sarigiannis K, Giri S,Munkarah AR, et al.Metformin limits the adipocyte tumor-promoting effect on ovarian cancer. Oncotarget 2014;5:4123-41.
36. Hu T, Chung YM, Guan M, Ma M, Ma J, Berek JS, et al. Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation. Sci Rep 2014;4:5810.
37. Erices R, Bravo ML, Gonzalez P, Olivia B, Racordon D, Garrido M, et al. Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells. Reprod Sci 2013:1-14.
38. Xie Y, Peng Z, Shi M, Ji M, Guo H, Shi H. Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin resistant ovarian cancer. Mol Med Rep 2014;10:2346-50.
39. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of metformin and the risk of ovarian cancer: A case-control analysis. Gynecol Oncol 2011;123:200-4.
40. Romero IL,McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 2012;119:61-7.
41. Kumar S, Meuter A, Thapa P, Langstraat C, Giri S, Chien J, et al. Metformin intake is associated with better survival in ovarian cancer: A case- control study. Cancer 2013;119:555-62.
42. Bakhru A, Buckanovich RJ, Griggs JJ. The impact of diabetes on survival in women with ovarian cancer. Gynecol Oncol 2011;121:106-11.
43. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: Review of the evidence and research perspectives. Ann N Y Acad Sci 2001;943:296-315.
44. Zhang Y, Liu H, Yang S, Zhang J, Qian L, Chen X. Overweight, obesity and endometrial cancer risk: Results from a systematic review and meta-analysis. Int J Biol Markers 2014;29:e21-9.
45. Rutanen EM. Insulin-like growth factors in endometrial function. Gynecol Endocrinol 1998;12:399-406.
46. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump V. Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol 2010;116:92-8.
47. Zhang Z, Dong L, Sui L, Yang Y, Liu X, Yu Y, et al. Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. Int J Gynecol Cancer 2011;21:213-21.
48. Hanna RK, Zhou C, Malloy KM, Sun L, Zhong Y, Gehrig PA, et al. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation on the mTOR pathway. Gynecol Oncol 2012;125: 458-69.
49. Iglesias DA, Yates MS, van der Hoeven D, Rodkey TL, Zhang Q, Co NN, et al. Another surprise from Metformin: Novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol Cancer Ther 2013;12:2847-56.
50. Sarfstein R, Friedman Y, Attias-Geva Z, Fishman A, Bruchim I, Werner H. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS One 2013;8:e61537.
51. Takahashi A, Kimura F, Yamanaka A, Takebayashi A, Kita N, Takahashi K, et al. Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer Cell Int 2014;14:53.
52. Tan BK, Adya R, Chen J, Lehnert H, Sant Cassia LJ, Randeva HS. Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab 2011;96:808-16.
53. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, et al. Altered PTEN expression as a diagnosticmarker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-30.
54. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 2003;10:203-8.
55. Hudes G, Carducci MA, Tomczac P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, Interferon Alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;365: 2271-81.
56. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of Everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
57. Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol 2010;117:473-6.
58. Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: A trial of the NCIC Clinical Trials Group. J Clin Oncol 2011;29:3278-85.
59. Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y, et al. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 2011;126:113-20.
60. Zhang Q, Celestino J, Schmandt R, McCampbell AS, Urbauer DL, Meyer LA, et al. Chemopreventive effects of metformin on obesity-associated endometrial proliferation. Am J Obstet Gynecol 2013;209(24):e1-12.
61. Becker C, Jick SS, Meier CR, Bodmer M. Metformin and the risk of endometrial cancer: A case-control analysis. Gynecol Oncol 2013;129:565-9.
62. Luo J, Beresford S, Chen C, Chlebowski R, Garcia L, Kuller L, et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer 2014;111:1432-9.
63. Ko EM,Walter P, Jackson A, Clark L, Franasiak J, Bolac C, et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 2014;132:438-42.
64. Nevadunsky NS, Van Arsdale A, Strickler HD,Moadel A, Kaur G, Frimer M, et al. Metformin use and endometrial cancer survival. Gynecol Oncol 2014;132:236-40.
65. Schuler KM, Rambally BS, Difurio MJ, Gehrig PA, Bae-Jump V. A preoperative window study of metformin for the treatment of endometrial cancer. J Clin Oncol 2013;31 (no. 15-suppl 5519).
66. Soliman PT, Broaddus R, Westin S, Iglesias D, Runsell M, Schmandt R. Phase 0 study: Prospective evaluation of the molecular effects of metformin on the endometriumin women with newly diagnosed endometrial cancer. Gynecol Oncol 2013;130:e1-169.
67. Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, et al. Antidiabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol Oncol 2014;134:607-14.
68. Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M. Effects of metformin on endometrial cancer cell growth in vivo: A preoperative prospective trial. Cancer 2014. http://dx.doi.org/10.1002/cncr.28853.
69. GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Internatonal Agency for Researach on Cancer, World Health Organization; 2012.
70. Gibb RK, Martens MG. The impact of liquid-based cytology in decreasing the incidence of cervical cancer. Rev Obstet Gynecol 2011;4:S2-S11.
71. Kurtz JE, Hardy-Bessard AC, Deslandres M, Lavau-Denes S, Largillier R, Roemer- Becuwe C, et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial. Gynecol Oncol 2009;113:16-20.
72. Faried LS, Faried A, Kanuma T, Sano T, Nakazato T, Tamura T, et al. Predictive and prognostic role of activatedmammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy. Oncol Rep 2006;16:57-63.
73. Faried LS, Faried A, Kanuma T, Aoki H, Sano T, Nakazato T, et al. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. Mol Carcinog 2008;47:446-57.
74. Kim MK, Kim TJ, Sung CO, Choi CH, Lee JW, Kim BG, et al. High expression of mTOR is associated with radiation resistance in cervical cancer. J Gynecol Oncol 2010;21: 181-5.
75. Tinker AV, Ellard S, Welch S, Moens F, Allo G, Tsao MS, et al. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecol Oncol 2013;130:269-74.
76. Xiao X, He Q, Lu C,Werle KD, Zhao RX, Chen J, et al. Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. Gynecol Oncol 2012;127:249-55.
77. Kwan HT, Chan DW, Cai PC, Mak CS, YungMM, Leung TH, et al. AMPK activators suppress cervical cancer cell growth through inhibition of DVL3 mediated Wnt/beta-catenin signaling activity. PLoS One 2013;8:e53597.
78. Yung MM, Chan DW, Liu VW, Yao KM, Ngan HY. Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade. BMC Cancer 2013;13:1-8.
79. Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T, et al. Somatic LKB1 mutations promote cervical cancer progression. PLoS One 2009;4:e5137.
80. Do MT, Kim HG, Khanal T, Choi JH, Kim DH, Jeong TC, et al. Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways. Toxicol Appl Pharmacol 2013;271:229-38.
81. NIH. http://clinicaltrials.gov/. (Accessed 2014 October).
82. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the anti-diabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745-52.
83. Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B, et al.Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 2014;508:108-12.
84. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg Effect: The metabolic requirements of cell proliferation. Science 2009;324:1029-31.
85. Niraula S, Dowling R, Ennis M, Chang MC, Done SJ, Hood N, et al. Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 2012;135:821-30.